Skip to content

Alumis Inc. ALMS Business Segments — Other Research And Development Expense

Similar metrics at other companies

Celldex Therapeutics logo
CLDXSingle Reportable — Other Research And Development Expense
$4.88M+48.9%
Lantheus Holdings logo
LNTHReportable — Other Research And Development Expense
$27.59M-1.1%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Other Research and Development Expense
$8.3M+23.2%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Other research and development
$4.84M+9.2%
Celldex Therapeutics logo
CLDXSingle Reportable — Research And Development Expense
$73M+38.7%
Merit Medical Systems logo
MMSISingle Reportable — Research And Development Expense
$22.61M+0.6%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s business segments — other research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s business segments — other research and development expense?
Alumis Inc. (ALMS) reported business segments — other research and development expense of $2.37M in Q1 2026.
How has Alumis Inc.'s business segments — other research and development expense changed year-over-year?
Alumis Inc.'s business segments — other research and development expense increased by 3.2% year-over-year, from $2.3M to $2.37M.
What is the long-term trend for Alumis Inc.'s business segments — other research and development expense?
Over 2 years (2023 to 2025), Alumis Inc.'s business segments — other research and development expense has grown at a -10.9% compound annual growth rate (CAGR), from $11.46M to $9.1M.
What does business segments — other research and development expense mean?
Encompasses miscellaneous research and development expenditures that do not fall into specific categories like personnel, facilities, or clinical trials. This metric provides visibility into the ancillary costs required to sustain the broader R&D infrastructure.